Welcome to our dedicated page for YIELD10 BISCIENCE NEW news (Ticker: YTEN), a resource for investors and traders seeking the latest updates and insights on YIELD10 BISCIENCE NEW stock.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) is a pioneering agricultural bioscience company focusing on the development of cutting-edge technologies for significant improvements in crop yield within the United States and Canada. Founded in 1992 and headquartered in Woburn, Massachusetts, Yield10 leverages advanced genetic engineering to develop high-value traits in seeds, targeting the agriculture and food industries through its Trait Factory. The company has a dedicated oilseed development center in Saskatchewan, Canada.
The core mission of Yield10 is to harness the genetic potential of the oilseed Camelina sativa ('Camelina') for the production of sustainable seed products. These products include feedstock oils for renewable diesel and sustainable aviation biofuels, omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical, and aquafeed applications, and future plans for PHA biomaterials to be used as biodegradable bioplastics.
Yield10’s research initiatives are bolstered by strategic partnerships with industry giants such as Bayer AG for soybean traits, Forage Genetics International, LLC for forage sorghum traits, J. R. Simplot Company for potato traits, and GDM Seeds Inc. for evaluating yield traits in soybeans. These collaborations underscore the company’s commitment to innovation and broadening the impact of its technologies.
Significant recent milestones include the development and successful field testing of proprietary winter Camelina varieties engineered for herbicide tolerance. These varieties showed promising results in tolerating glufosinate and Group 2 herbicides, which are crucial for managing weeds and ensuring high yield in crop rotations across North America. This advancement is expected to facilitate the large-scale adoption of Camelina for biofuel and omega-3 oil markets, with the potential for commercial production as early as 2025.
Regulatory progress has been a key aspect of Yield10’s strategy, with USDA-APHIS determining that its genetically engineered Camelina traits are not subject to certain regulations, allowing for expanded planting and breeding in the United States. Additionally, the Canadian Food Inspection Agency has cleared Yield10's E3902 Camelina, which features enhanced oil production and a lighter seed coat.
Yield10 continues to build on its commercial and regulatory achievements, exemplified by the recent agreement with Vision Bioenergy Oilseeds to license Camelina varieties for biofuel feedstock production. This collaboration aims to support the growing demand for low-carbon intensity feedstock oil, aligning with global decarbonization goals.
For more detailed information about Yield10 Bioscience and its innovative endeavors, visit www.yield10bio.com or follow the company on X (formerly Twitter), Facebook, and LinkedIn.
Yield10 Bioscience (YTEN) announced the upcoming release of its second quarter 2022 financial results on August 10, 2022. The Company will provide a corporate update during a conference call scheduled for 4:30 p.m. ET. Investors can participate by calling a designated number or accessing a live webcast. A replay of the call will be available until August 24, 2022. Yield10 focuses on developing improved Camelina varieties and aims to establish a high-value seed products business for agricultural applications.
Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced the renaming of its Canadian subsidiary to Yield10 Oilseeds Inc. on July 12, 2022. This branding alignment highlights their focus on innovation in oilseed crops, aiming to enhance global food security and address environmental challenges. Established in 2010 and located in Saskatoon, Yield10 Oilseeds is responsible for developing and field-testing Camelina varieties with traits for biofuels and animal feed. CEO Oliver Peoples emphasized this step to strengthen grower engagement and expand Camelina production.
Yield10 Bioscience, an agricultural bioscience company, announced that its Chief Science Officer, Dr. Kristi Snell, will present at the CROPS 2022 Conference in Huntsville, Alabama, on June 15. Her presentation, titled "Breakthroughs in Plant Based Polyhydroxybutyrate (PHB) Production," focuses on the sustainable production of PHA bioplastics in Camelina seeds. Yield10's research indicates PHA yields of up to 10.2% in Camelina seeds, with ongoing developments aimed at achieving 10-20% yields. This innovation could open new market opportunities for farmers and address global plastic waste issues.
Yield10 Bioscience (Nasdaq: YTEN) announced that its President and CEO, Oliver Peoples, Ph.D., will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference, taking place from May 23-26, 2022, at the Fontainebleau Hotel in Miami Beach, FL. The presentation will be available on demand starting at 7:00 am ET on May 24 through May 26. Yield10 focuses on agricultural bioscience, aiming to develop improved Camelina varieties for renewable diesel, bioplastics, and omega-3 oils. More information is available on their website.
Yield10 Bioscience (Nasdaq:YTEN) reported a net loss of $3.3 million for Q1 2022, increased from a net loss of $2.6 million a year prior. Cash and investments decreased to $12.7 million, prompting the company to estimate total net cash usage between $12.0 and $12.5 million for the full year. Key developments include hiring Darren Greenfield as senior director of seed operations and ongoing efforts to commercialize Camelina for biofuel and omega-3 oil markets. The ongoing geopolitical and COVID-19 challenges may impact operations, but the company remains focused on its objectives.
Yield10 Bioscience, Inc. (Nasdaq:YTEN) will report its Q1 2022 financial results on May 11, 2022. Following the earnings announcement, management will host a conference call at 4:30 p.m. ET to discuss financial highlights and provide a business update. Interested parties can access the live call by phone or via a webcast. A replay will be available shortly after the call, lasting until May 25, 2022. Yield10 focuses on developing improved Camelina varieties using its 'Trait Factory' platform for agricultural and food industry applications.
Yield10 Bioscience announced the appointment of Willie Loh, Ph.D., as a special advisor to its Board of Directors and Management, effective immediately. Loh brings extensive experience from Cargill's Global Edible Oils Division, where he focused on market development for oils. His expertise is particularly significant as Yield10 aims to commercialize its Camelina oil platform amidst rising global vegetable oil demand, driven by biofuels and human nutrition. Loh's strategic insights are expected to enhance Yield10's market engagement as they progress towards commercialization.
Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced that President and CEO Oliver Peoples will participate in the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. Dr. Peoples is set to present a corporate overview, available at 9:00 am ET on March 28. Additionally, he will engage in a live fireside chat with Anthony Vendetti at 11:30 am ET on the same day. Investors can register for the conference and request one-on-one meetings with management. Yield10 focuses on agricultural bioscience, developing improved Camelina varieties and high-value genetic traits.
Yield10 Bioscience (Nasdaq: YTEN) announced its focus on Camelina as a renewable source of feedstock oil for the biofuels market in the U.S. and Canada. The company’s CEO, Dr. Oliver Peoples, presented at the Advanced Bioeconomy Leadership Conference 2022, emphasizing Camelina's sustainability benefits and its potential for low-carbon biofuels. Yield10 aims to escalate Camelina seed production and collaborate with supply chain partners. The company published a white paper outlining its biofuels and bioplastics development strategy.
Yield10 Bioscience (Nasdaq:YTEN) reported its financial results for 2021, emphasizing its focus on commercializing Camelina for renewable diesel production. The company achieved a net loss of $11.0 million, or $2.33 per share, compared to a loss of $10.2 million in 2020. Cash on hand increased to $16.0 million from $9.7 million year-over-year. Yield10 is advancing its research in PHA bioplastics and omega-3 oils, with plans for a 2022 field test program and ongoing commercialization activities despite potential COVID-19 impacts.
FAQ
What is the current stock price of YIELD10 BISCIENCE NEW (YTEN)?
What is the market cap of YIELD10 BISCIENCE NEW (YTEN)?
What does Yield10 Bioscience do?
Where is Yield10 Bioscience headquartered?
What are some recent achievements of Yield10 Bioscience?
Who are Yield10 Bioscience’s key partners?
What is Camelina sativa?
What is the significance of Yield10’s herbicide tolerance tests?
What are Yield10’s future plans for Camelina?
What regulatory milestones has Yield10 achieved?
How is Yield10 addressing the demand for omega-3 oils?
Where can I find more information about Yield10 Bioscience?
